Results 71 to 80 of about 36,119 (263)

Safety and Efficacy Assessment of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2‐Positive Unresectable Locally Advanced or Metastatic Breast Cancer Previously Treated With Trastuzumab and a Taxane: An Open‐Label, Single‐Arm, Phase IV Study

Asia-Pacific Journal of Clinical Oncology, EarlyView.
A phase IV, single‐arm, open‐label, multicenter study assessing the safety and efficacy of trastuzumab emtansine in Indian patients for the treatment of human epidermal growth factor receptor 2 (HER2)‐positive unresectable locally advanced or metastatic breast cancer who received prior treatment with trastuzumab and a taxane.
Sudeep Gupta, Manish Singhal, Shona Nag, Waseem Abbas, Dinesh Chandra Doval, Hari Goyal, Chirag Shah, Ashish Singh, Radheshyam Naik, Nitesh Rohatgi, Poonam Patil, Shyam Aggarwal, Vinod Raina, Vaibhav Watts   +13 more
wiley   +1 more source

Managing menopausal symptoms and associated clinical issues in breast cancer survivors [PDF]

, 2017
Objective: Review evidence to guide management of menopausal signs and symptoms in women after breast cancer and make recommendations accordingly. Evidence: Randomized controlled clinical trials, observational studies, evidence-based guidelines, and
Davis, Susan R., Gompel, Anne, Lumsden, Mary Ann, Pinkerton, JoAnn V., Santen, Richard J., Stuenkel, Cynthia A.   +5 more
core   +1 more source

Four‐Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI‐52

Cancer Science, EarlyView.
This follow‐up study for TASUKI‐52 trial demonstrates the 4‐year beneficial efficacy of nivolumab (NIV) combined with chemotherapy (CP) and bevacizumab (BEV) in patients with nonsquamous non‐small cell lung cancer (NSCLC) and reveals potential patient backgrounds associated with long‐term survival.
Jong‐Seok Lee, Shunichi Sugawara, Jin‐Hyoung Kang, Hye Ryun Kim, Naoki Inui, Toyoaki Hida, Ki Hyeong Lee, Tatsuya Yoshida, Hiroshi Tanaka, Cheng‐Ta Yang, Takako Inoue, Makoto Nishio, Yasushi Goto, Tomohide Tamura, Nobuyuki Yamamoto, Chong‐Jen Yu, Hiroaki Akamatsu, Shigeru Takahashi, Kazuhiko Nakagawa   +18 more
wiley   +1 more source

Effects of 3-year denosumab treatment on hip structure in Japanese postmenopausal women and men with osteoporosis

Bone Reports, 2017
Denosumab, a human monoclonal antibody against RANK ligand, is shown to have strong anti-fracture effects in Japanese osteoporosis patients. However, there have been no data showing actions on Japanese bone architecture.
Teruki Sone, Naohiro Kon, Kenneth W. Gaither, Naoki Okubo, Taisuke Osakabe, Yutaka Nakayama, Masao Fukunaga, Masako Ito, Toshitaka Nakamura   +8 more
doaj   +1 more source

Novel genetic models of osteoporosis by overexpression of human rankl in transgenic mice [PDF]

, 2014
Receptor activator of NF-KB ligand (RANKL) plays a key role in osteoclast-induced bone resorption across a range of degenerative bone diseases, and its specific inhibition has been recently approved as a treatment for women with postmenopausal ...
Bonnet, Nicolas, Dacquin, Romain, Douni, Eleni, Ferrari, Serge, Han, Chun-Ya, Jurdic, Pierre, Kostenuik, Paul, Niti, Alexandra, Rinotas, Vagelis, Stolina, Marina   +9 more
core   +2 more sources

Clinical Practice Patterns in Bone Health Assessment and Management in Endogenous Cushing's Syndrome

Clinical Endocrinology, EarlyView.
ABSTRACT Objective Skeletal fragility is a common complication of endogenous Cushing's Syndrome (CS), although specific guidelines for managing bone health are lacking. This study aimed to assess clinicians' current engagement with bone health assessment and management in patients with endogenous CS. Design Retrospective‐cohort design. Patients Seventy‐
Preeshila Behary, Dinushan Raveendran, Ramesh Nair, Aimee Di Marco, Debbie Papadopoulou, Florian Wernig, Ali Abbara, Karim Meeran, Niamh Martin, Jeremy Cox, Alexander N. Comninos   +10 more
wiley   +1 more source

Denosumab Can Prevent Collapse in Patients with Early‐Stage Steroid‐Induced Osteonecrosis of the Femoral Head by Inhibiting Osteoclasts and Autophagy

Orthopaedic Surgery, 2023
Objective The osteoclastic bone resorption inhibitors might have positive effect in preventing femoral head collapse in patients with osteonecrosis of the femoral head (ONFH).
Bo Liu, Feng Gao, Xiaofei Xiu, Tao Wu, Zeming Liu, Bingshi Zhang, Sikai Liu, Yongtai Han   +7 more
doaj   +1 more source

Application Strategies of Bone Marrow Mesenchymal Stromal Cells in Bone‐Related Diseases

Cell Proliferation, EarlyView.
Engineered BMSCs and vesicles enhance therapy effects for bone diseases via multi‐strategic approaches. ABSTRACT Bone‐related diseases (e.g., osteoporosis, osteoarthritis and fractures) exhibit a rising global incidence, imposing significant burdens on both quality of life and healthcare systems.
Xuemei Long, Dan Tan, Qianke Tao, Qiaonan Ye, Luwen Ye, Qing Li, Jingang Xiao   +6 more
wiley   +1 more source

Physicians’ Preferences for Bone Metastases Drug Therapy in the United States [PDF]

, 2015
ObjectiveSeveral characteristics of bone-targeted agents are considered when making treatment decisions. This study evaluated physicians’ therapy preferences for preventing skeletal-related events (SREs) in patients with bone metastases secondary to ...
Arellano, Jorge, Hauber, A. Brett, Mohamed, Ateesha F., Gonzalez, Juan Marcos, Collins, Helen, Hechmati, Guy, Gatta, Francesca, Qian, Yi   +7 more
core   +1 more source

Alterations of bone proteins in medication‐related osteonecrosis of the jaw

European Journal of Oral Sciences, Volume 133, Issue 2, April 2025.
Abstract Changes in the protein expression pattern of osteoblastic lineage cells from the alveolar bone (OLAB) during medication‐related osteonecrosis of the jaw (MRONJ) have rarely been investigated. This lack of information is partly because of the limited availability of healthy samples and the lack of human alveolar bone cell lines for research ...
Andrea Schubert, Phillipp Brockmeyer, Philipp Kauffmann, Jan Wiegel, Florian Lautenbacher, Nicolai Miosge, Boris Schminke   +6 more
wiley   +1 more source